BPI France launches AdvanThink as part of the France 2030 adventure!

AdvanThink is a French player, a pioneer in artificial intelligence and a leader in fraud detection. Thanks to its 35 years of expertise in Data, AI and Healthcare, the company has been selected by the BPI to contribute to the growth of French Healthcare R&D.

The INNOV UP project:

Since January 2022, Advanthink has focused its efforts on the healthcare field, and more specifically on multi-omics data analysis. The aim is to draw on Data Science and exploit Business Expertise to extract new information and, in so doing, better understand the underlying mechanisms linked to a given physio-pathological context.

Thanks to our Amadea platform, we approach our work as data artisans: we reference data, interpret it, explain it and derive information that enables us to understand the underlying mechanisms linked to a given physio-pathological context. Our approach is meticulous and profound. It differs from generic approaches, and systematically allows us to find the improbable, to unleash the extraordinary in what we have on hand: "data is the key!

The Amadea platform for managing and exploiting data/IA has been intrinsically linked to advances in healthcare for almost 30 years. It is used by numerous laboratories and experts in the field for research, and will naturally be used for this new work.

Brice Perdrix, CEO of AdvanThink, states:
"We are honored to receive recognition from the BPI, which values our research and development efforts in the field of AI applied to biological and medical issues."

Jean-Philippe MEYNIEL, PhD, BU Life Science Manager

"Concepts and knowledge evolve very rapidly in Biology. Implementing analysis tools that can keep ahead of these developments is a real challenge.

Advanthink has used its skills to specialize its Model Factory as a tool for industrial performance: optimizing Machine Learning models, comparing and classifying them, and ensuring that they evolve as research progresses. Taking into account new work and new data completes the technological set-up in place, bringing convincing advances in the understanding and analysis of this particularly complex field.

This partnership between BPI France and Advanthink will enable us to rapidly focus our efforts on results, and already predicts major advances in our understanding of biological mechanisms and in the treatment of numerous pathologies.